Five-year relative survival by race and cancer type
Cancer type . | Race . | No. of patients . | Relative survival adjusted for age (%) . | 95% CI . |
---|---|---|---|---|
NHL | Non-Hispanic white | 141 319 | 69 | 69-70 |
Black | 15 719 | 59 | 57-60 | |
Hispanic white | 21 673 | 62 | 61-63 | |
Asian | 12 479 | 62 | 60-63 | |
Myeloma | Non-Hispanic white | 39 461 | 46 | 45-47 |
Black | 12 253 | 43 | 42-44 | |
Hispanic white | 6 702 | 43 | 41-44 | |
Asian | 3 453 | 44 | 42-46 | |
AML | Non-Hispanic white | 23 217 | 18 | 18-19 |
Black | 2 851 | 15 | 14-17 | |
Hispanic white | 4 014 | 17 | 16-19 | |
Asian | 2 677 | 18 | 16-19 | |
HL | Non-Hispanic white | 20 080 | 84 | 84-85 |
Black | 3 567 | 77 | 75-79 | |
Hispanic white | 4 276 | 79 | 77-80 | |
Asian | 1 412 | 80 | 78-83 | |
ALL | Non-Hispanic white | 4 520 | 44 | 42-45 |
Black | 628 | 33 | 29-37 | |
Hispanic white | 2 808 | 34 | 32-36 | |
Asian | 657 | 43 | 39-47 |
Cancer type . | Race . | No. of patients . | Relative survival adjusted for age (%) . | 95% CI . |
---|---|---|---|---|
NHL | Non-Hispanic white | 141 319 | 69 | 69-70 |
Black | 15 719 | 59 | 57-60 | |
Hispanic white | 21 673 | 62 | 61-63 | |
Asian | 12 479 | 62 | 60-63 | |
Myeloma | Non-Hispanic white | 39 461 | 46 | 45-47 |
Black | 12 253 | 43 | 42-44 | |
Hispanic white | 6 702 | 43 | 41-44 | |
Asian | 3 453 | 44 | 42-46 | |
AML | Non-Hispanic white | 23 217 | 18 | 18-19 |
Black | 2 851 | 15 | 14-17 | |
Hispanic white | 4 014 | 17 | 16-19 | |
Asian | 2 677 | 18 | 16-19 | |
HL | Non-Hispanic white | 20 080 | 84 | 84-85 |
Black | 3 567 | 77 | 75-79 | |
Hispanic white | 4 276 | 79 | 77-80 | |
Asian | 1 412 | 80 | 78-83 | |
ALL | Non-Hispanic white | 4 520 | 44 | 42-45 |
Black | 628 | 33 | 29-37 | |
Hispanic white | 2 808 | 34 | 32-36 | |
Asian | 657 | 43 | 39-47 |
Data from SEER 18 (2000-2014) showing 5-year relative survival of patients with selected malignancies stratified by race. Data were age-standardized to the International Cancer Survival Standard 1 (ICSS-1) for age 15 years or older except for ALL and HL which used ICSS-3. Age standardization allows comparison of outcomes for the different races/ethnicities adjusting for different age distributions for those groups.12